Literature DB >> 8145045

Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.

X G Zhang1, J J Gu, Z Y Lu, K Yasukawa, G D Yancopoulos, K Turner, M Shoyab, T Taga, T Kishimoto, R Bataille.   

Abstract

Interleukin 6 (IL-6) is a major growth factor for tumor plasma cells involved in human multiple myeloma (MM). In particular, human myeloma cell lines (HMCL), whose growth is completely dependent on addition of exogenous IL-6, can be obtained reproducibly from every patient with terminal disease. Four cytokines, ciliary neurotropic factor (CNTF), IL-11, leukemia inhibitory factor (LIF), and oncostatin M (OM), use the same transducer chain (signal transducer gp130) as IL-6 and share numerous biological activities with this IL. We found that these four cytokines stimulated proliferation and supported the long-term growth of two out of four IL-6-dependent HMCL obtained in our laboratory. Half-maximal proliferation was obtained with cytokine concentrations ranging from 0.4 to 1.2 ng/ml for IL-11, LIF, and OM. CNTF worked at high concentrations only (90 ng/ml), but addition of soluble CNTF receptor increased sensitivity to CNTF 30-fold. The growth-promoting effect of these four cytokines was abrogated by anti-gp130 antibodies, contrary to results for anti-IL-6 receptor or anti-IL-6 antibodies. No detectable changes in the morphology and phenotype were found when myeloma cells were cultured with one of these four cytokines instead of IL-6. Concordant with their IL-6-dependent growth, the four HMCL expressed membrane IL-6R and gp130 detected by FACS analysis. LIF-binding chain gene (LIFR) was expressed only in the two HMCL responsive to LIF and OM.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145045      PMCID: PMC2191454          DOI: 10.1084/jem.179.4.1337

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  25 in total

1.  Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies.

Authors:  Y Hirata; T Taga; M Hibi; N Nakano; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

2.  The receptor for ciliary neurotrophic factor.

Authors:  S Davis; T H Aldrich; D M Valenzuela; V V Wong; M E Furth; S P Squinto; G D Yancopoulos
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

Review 3.  Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma.

Authors:  B Klein; X G Zhang; M Jourdan; J M Boiron; M Portier; Z Y Lu; J Wijdenes; J Brochier; R Bataille
Journal:  Eur Cytokine Netw       Date:  1990 Oct-Nov       Impact factor: 2.737

4.  Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia.

Authors:  B Klein; J Wijdenes; X G Zhang; M Jourdan; J M Boiron; J Brochier; J Liautard; M Merlin; C Clement; B Morel-Fournier
Journal:  Blood       Date:  1991-09-01       Impact factor: 22.113

5.  CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130.

Authors:  N Y Ip; S H Nye; T G Boulton; S Davis; T Taga; Y Li; S J Birren; K Yasukawa; T Kishimoto; D J Anderson
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

Review 6.  Biological and clinical aspects of interleukin 6.

Authors:  T Hirano; S Akira; T Taga; T Kishimoto
Journal:  Immunol Today       Date:  1990-12

7.  Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.

Authors:  R Bataille; M Jourdan; X G Zhang; B Klein
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

8.  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.

Authors:  K Yamasaki; T Taga; Y Hirata; H Yawata; Y Kawanishi; B Seed; T Taniguchi; T Hirano; T Kishimoto
Journal:  Science       Date:  1988-08-12       Impact factor: 47.728

9.  IFN-alpha induces autocrine production of IL-6 in myeloma cell lines.

Authors:  M Jourdan; X G Zhang; M Portier; J M Boiron; R Bataille; B Klein
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

10.  Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130.

Authors:  D P Gearing; C J Thut; T VandeBos; S D Gimpel; P B Delaney; J King; V Price; D Cosman; M P Beckmann
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

View more
  31 in total

1.  Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer.

Authors:  Nicole Deutscher; Frauke Bataille; Martin Hausmann; Stephan Kiessling; Gerhard Muller-Newen; Sandra N Leeb; Hans Herfarth; Peter C Heinrich; Jürgen Schölmerich; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2005-11-15       Impact factor: 2.571

2.  Endothelium-derived GM-CSF influences expression of oncostatin M.

Authors:  Wafa M Elbjeirami; Elizabeth M Donnachie; Alan R Burns; C Wayne Smith
Journal:  Am J Physiol Cell Physiol       Date:  2011-07-20       Impact factor: 4.249

Review 3.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

4.  Molecular characterization and expression analysis of the putative interleukin 6 receptor (IL-6Rα and glycoprotein-130) in rainbow trout (Oncorhynchus mykiss): salmonid IL-6Rα possesses a polymorphic N-terminal Ig domain with variable numbers of two repeats.

Authors:  Maria M Costa; Tiehui Wang; Milena M Monte; Christopher J Secombes
Journal:  Immunogenetics       Date:  2011-10-29       Impact factor: 2.846

5.  Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction.

Authors:  W Tang; G P Geba; T Zheng; P Ray; R J Homer; C Kuhn; R A Flavell; J A Elias
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

6.  Functional characterization of W147A: a high-affinity interleukin-11 antagonist.

Authors:  Nicholas Underhill-Day; Lisa A McGovern; Natalia Karpovich; Helen J Mardon; Victoria A Barton; John K Heath
Journal:  Endocrinology       Date:  2003-08       Impact factor: 4.736

7.  Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women.

Authors:  B K Patterson; H Behbahani; W J Kabat; Y Sullivan; M R O'Gorman; A Landay; Z Flener; N Khan; R Yogev; J Andersson
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

8.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

9.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

10.  T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

Authors:  D M Hilbert; M Y Shen; U R Rapp; S Rudikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.